Navigation Links
Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

stablishing appropriate doses for our later-stage clinical study, and I am pleased to say we accomplished both,” said Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. “DDP733, which targets the GI motility abnormalities central to GERD, has demonstrated a statistically significant reduction in the number of reflux events at a dose of 0.5 mg in this trial. We are now planning a larger Phase 2 study in GERD patients, where we will further build on these very promising results.”

In February of this year, Dynogen announced positive results from its Phase 2 study of DDP733 in IBS-c, with a statistically significant improvement over placebo in the Subject Global Assessment of IBS. The Company plans to initiate a Phase 2b study in IBS-c this year.

About DDP733

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract). Dynogen’s preclinical studies have also shown that DDP733 is minimally absorbed by the cells lining the gastrointestinal tract and, as a result, more of the product candidate remains available at the desired local site of action. A recently completed Phase 2 study of the candidate as a treatment for IBS-c demonstrated an overall clinical response rate of 54% in patients receiving a dose of 1.4 mg t.i.d. compared to a 15% clinical response rate for patients receiving placebo, and the drug was also well-tolerated. Previous clinical studies of the compound have demonstrated favorable safety and pharmacokinetic profiles. Dynogen has exclusive rights under issued U.S. and European patents related to the use of DDP733 as a treatment for GERD.

About Nocturnal Gastroesophageal Reflux Dis
'"/>




Page: 1 2 3

Related medicine technology :

1. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
2. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
5. Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen DDP733 Reduces Reflux Phase GERD Study
(Date:4/17/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of cancer and diseases of the ... from three of its most advanced oncology programs at ... th Annual Meeting being held from April 18-22, ... The presentation on the BNC105 program ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 Vanda ... company focused on the development and commercialization of products ... announced it will release results for the first quarter ... market closes. The Company will host ... May 6, 2015, during which Vanda management will discuss ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 A drug ... the eyesight of people with multiple sclerosis (MS), according to ... American Academy of Neurology,s 67th Annual Meeting in ... "About half of people with MS experience at ... neuritis, in which the nerve carrying vision from the eye ...
Breaking Medicine Technology:Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Epilepsy Drug May Preserve Eyesight for People with MS 2
(Date:4/18/2015)... "I wanted to live a healthier ... juice that contained essential vitamins, minerals and nutrients," ... my energy, improves skin elasticity and gives me ... Juice to contain fruits, vegetables and other healthful ... mental fatigue. It features a great taste. The ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 On April 14th, ... Threat Report , which they say, “exposes a tactical shift ... new malware variants were introduced in 2014 - almost a ... Zero Day threats to be identified and patched by prominent ... abundantly clear that doing business in a digital world can ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark ... other secure destruction professionals across the United States, earned ... will now display “CSDS” as a professional title with ... National Association of Information Destruction 2015 Annual Conference began ... Of the 20 people who took the exam, Ona ...
Breaking Medicine News(10 mins):Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... don't feel well prepared to make the decision to ... of life // , reports a study in the ... ,Nephrologists who are more experienced and more familiar ... the Renal Physicians Association and the American Society of ...
... containing rhubarb extract could minimize the severity of hot ... perimenopausal women to determine the usefulness of rhubarb extracts. ... extract, while the other half took a placebo for ... pill, had less severe hot flashes than the placebo ...
... new study says that drinking alcohol is linked to ... of drinking//. ,"Social drinking builds social capital," ... Jose State University. "Social drinkers are out networking, ... result in bigger paychecks." ,The researchers said that ...
... lung quality as part of the San Antonio Lung ... available donor lungs and transplant procedures without compromising recipient ... ,The study appears in the second issue for ... Critical Care Medicine, published by the American Thoracic Society. ...
... a further risk of further strokes if they suffer high ... strokes could also disable nearly 50% of the patients. , ... said” Stroke incidence and mortality are generally disproportionately higher among ... be explained by a greater vascular risk among African Americans.” ...
... key chemicals on the inner lining of the nose ... to the usual current treatments according// to researchers at ... million Americans know the misery of persistent inflammation of ... cavities. The result is clogged passages and recurring infections, ...
Cached Medicine News:Health News:Many Kidney Specialists Feel Unprepared for End-of-Life Decisions 2Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
Incontinence Pessaries...
Incontinence Pessaries...
HODGE with support designed for patient with limited pubic notch and mild cystocele. The folding HODGE Pessary with Support is indicated for the woman with stress urinary incontinence with a mild cyc...
Indications: for young women who experience stress urinary incontinence when excercising vigorously; i.e., aerobics, tennis, jogging....
Medicine Products: